Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Barchas Isaac 2. Issuer Name and Ticker or Trading Symbol Immunome Inc. [IMNM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100 3. Date of Earliest Transaction (Month/Day/Year) 12/22/2025 (Street) BOTHELL, WA 98011 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/22/2025 S(1) 371,949(2) D $21.72(3) 2,042,432(4) I See footnotes(5) Common Stock 12/22/2025 S(1) 11,251(6) D $22.34(7) 2,031,181(8) I See footnote(5) Common Stock 92,211(9) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Barchas Isaac C/O IMMUNOME, INC. 18702 N. CREEK PARKWAY, SUITE 100 BOTHELL, WA 98011	X

Signatures

/s/ Sandra Stoneman, Attorney-in-Fact		12/23/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2024.
(2)	The shares were sold as follows: 226,480 shares were sold by Arsenal Bridge Venture II, LLC ("ABV II") and 145,469 shares were sold by Arsenal Bridge Venture II-B, LLC ("ABV II-B" and collectively with ABV II, the "ABV Entities").
(3)	The weighted average sale price for the transaction report was $21.72, and the range of prices were between $21.31 and $22.30, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
(4)	Following this transaction, ABV II and ABV II-B own 1,245,133 shares of Issuer common stock and 797,299 shares of Issuer common stock, respectively.
(5)	Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares.
(6)	The shares were sold as follows: 6,851 shares were sold by ABV II and 4,400 shares were sold by ABV II-B.
(7)	The weighted average sale price for the transaction report was $22.34, and the range of prices were between $22.31 and $22.38, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
(8)	Following this transaction, ABV II and ABV II-B own 1,238,282 shares of Issuer common stock and 792,899 shares of Issuer common stock, respectively.
(9)	Since the date of the Reporting Person's last ownership report, he transferred 29,469 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
Remarks: On the basis of the relationship between Mr. Barchas and the ABV Entities, the ABV Entities may be subject to Section 16 of the Exchange Act with respect to the Issuer as so-called directors by deputization.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.